These findings indicate that AS-IV may have the ability to mitigate tubular damage, attenuate lipid accumulation, reduce the production of ROS, suppress the activation of the NLRP3 inflammatory body and the expression of GSDMD by downregulating CD36 expression in both PA-induced HK-2 cells and DKD rats. This evidence concerns the gene CD36 and diabetic kidney disease.